secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2025-01-29T23:59:59+00:00
Accession:  0001193125-25-014985
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Allogene Therapeutics officer Timothy Moore to depart Feb 28, 2025
------------------------------------------------------------------

- Timothy Moore leaving employment on February 28, 2025; departure treated as termination without cause.
- Eligible for cash severance and COBRA reimbursement under the company's Change in Control and Severance Benefit Plan, subject to release.
- Company intends to enter into a consulting agreement with Moore, terms to be mutually agreed.
- No immediate replacement for Moore has been announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000119312525014985/0001193125-25-014985-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000119312525014985/d932314d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-014985

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer